SCHEMBL30717355

SCHEMBL30717355

CCN1CCN(c2nc3c(s2)CN(C(=O)CC(C)(C)C)CC3)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.43
RAB9A P51151 5/20 0.43
GRM5 P41594 3/20 0.41
OGA O60502 2/20 0.41
RAD52 P43351 1/20 0.39
RECQL P46063 1/20 0.39
GAA P10253 3/20 0.37
POLB P06746 2/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2D6 P10635 2/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 3/20 0.35
MAPT P10636 3/20 0.35
KMT2A Q03164 3/20 0.35
HPGD P15428 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
LMNA P02545 1/20 0.34
MITF O75030 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30717620 0.85 NPC1 (0.42) NPC1RAB9AGRM5OGAGAA
SCHEMBL12199712 0.85 OGA (0.53) NPC1RAB9AGRM5OGARAD52
SCHEMBL30717561 0.84 GRAMD1A (0.43) NPC1RAB9AGRM5OGAMAPT
SCHEMBL12199715 0.83 GRAMD1A (0.46) NPC1RAB9AOGARAD52RECQL
SCHEMBL12199710 0.81 GRM5 (0.49) NPC1RAB9AGRM5OGASMN1; SMN2
SCHEMBL13494234 0.78 DPP4 (0.49) NPC1RAB9AGRM5GAASMN1; SMN2
SCHEMBL12199709 0.77 POLB (0.40) NPC1RAB9AGRM5OGARAD52
SCHEMBL30717419 0.75 NPC1 (0.39) NPC1RAB9AGRM5OGADPP4
SCHEMBL12199714 0.75 HDAC3 (0.49) GRM5OGAGAASMN1; SMN2ALDH1A1
SCHEMBL30790958 0.75 HSP90AA1 (0.42) GRM5MAPTLMNAACKR3HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4572762-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS Mironid Limited (GB) 2025-06-25 EP claimed
WO-2024038128-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS MIRONID LIMITED (GB) 2024-02-22 WO claimed
US-20250388604-A1 Compounds and Their Use as PDE4 Activators MIRONID LIMITED (GB) 2025-12-25 US disclosed
EP-4572762-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS Mironid Limited (GB) 2025-06-25 EP disclosed
WO-2024038128-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS MIRONID LIMITED (GB) 2024-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388604-A1 Compounds and Their Use as PDE4 Activators PDE4A, PDE7A, PDE4B NPC1 3054/4885RAB9A 701/4885GRM5 2029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.